1. Search Result
Search Result
Results for "

cyclin-dependent

" in MedChemExpress (MCE) Product Catalog:

118

Inhibitors & Agonists

3

Peptides

2

Natural
Products

67

Recombinant Proteins

38

Antibodies

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-108136A
    Bisindolylmaleimide X hydrochloride
    2 Publications Verification

    BIM-X hydrochloride; Ro31-8425 hydrochloride

    PKC CDK Cardiovascular Disease
    Bisindolylmaleimide X hydrochloride (BIM-X hydrochloride) is a potent and selective protein kinase C (PKC) inhibitor. Bisindolylmaleimide X hydrochloride is a potent cyclin-dependent kinase 2 (CDK2) antagonist with an IC50 of 200 nM .
    Bisindolylmaleimide X hydrochloride
  • HY-18299B

    (S)-NG 95

    Drug Isomer Others
    (S)-Purvalanol B is the S enantiomer of Purvalanol B. Purvalanol B is a cyclin-dependent kinase inhibitor.
    (S)-Purvalanol B
  • HY-139342

    CDK Cancer
    CDK7-IN-4 (compound I) is a potent CDK7 (Cyclin-dependent kinase 7) inhibitor. CDK7-IN-4 shows anticancer activity. CDK7-IN-4 inhibits the in vitro growth of cancer cell lines from a variety of histologies including colon , breast , lung , ovary and stomach , in a dose dependent manner .
    CDK7-IN-4
  • HY-114177A

    (S)-PF-06873600

    CDK Cancer
    (S)-PF-06873600 it the S enantiomer of PF-06873600. PF-06873600 is a selective and orally bioavailable inhibitor of cyclin-dependent kinase (CDK).
    (S)-Ebvaciclib
  • HY-172245

    CDK Cancer
    Zeltociclib is a cyclin-dependent kinase inhibitor with antitumor effects .
    Zeltociclib
  • HY-149261

    Autophagy CDK Cancer
    H1k, a Eudistomin Y derivative, is a lysosome-targeted antiproliferation agent. H1k increases the autophagy signal and downregulate the expression of cyclin-dependent kinase (CDK1) and cyclin B1. H1k can be used in research of cancer .
    H1k
  • HY-146213

    CDK Cancer
    CDK4/6-IN-12 is a potent cyclin-dependent kinase 4/6 (CDK4/6) inhibitor. CDK4/6-IN-12 has enzymatic inhibitory activity for CDK4 and CDK6 with IC50 of 592.3 nM and 3090 nM, respectively. CDK4/6-IN-12 can be used for the research of cancer .
    CDK4/6-IN-12
  • HY-170442

    CDK Cancer
    CDK2-IN-37 (COMPOUND 2) is a cyclin-dependent kinase (CDK2) inhibitor with anti-cancer activity .
    CDK2-IN-37
  • HY-162270

    CDK Cancer
    CDK2-IN-24 (compound 3f) is an inhibitor of cyclin-dependent kinase 2 with an elevated binding energy value .
    CDK2-IN-24
  • HY-P5428

    CDK Others
    Cdc2 kinase substrate is a biological active peptide. (The native peptide HATPPKKKRK is a substrate for cyclin-dependent protein kinase 1 (CDC2; CDK1).)
    Cdc2 kinase substrate
  • HY-169557

    CDK Neurological Disease
    CDKI-IN-1 (Compound SNX12) is a cyclin-dependent kinase inhibitor (CDKI) inhibitor that can be used for research into degenerative diseases of the central nervous system .
    CDKI-IN-1
  • HY-163170

    CDK Cancer
    FMF-04-159-R is a cyclin-dependent kinase CDK14 and CDK16 inhibitor with IC50 values of 5.9 and 139.1 nM .
    FMF-04-159-R
  • HY-153596

    CDK Cancer
    SNX7 is a Cyclin-Dependent Kinase Inhibitor (CDKI) pathway inhibitor. SNX7 can be used for research of senescence-related and other CDKI-related diseases .
    SNX7
  • HY-E70689

    CDK Cancer
    CDK7/CycH/MAT1 Recombinant Human Active Protein Kinase acts as a cyclin-dependent kinase activating kinase. CDK7 exists in several forms including a core tri-partite CDK7/CycH/MAT1 complex known as CAK (cyclin-dependent kinase activating kinase), as a component in the general transcription factor TFIIH and as a component of larger complexes containing pol II and other transcription factors .
    CDK7/CycH/MAT1 Recombinant Human Active Protein Kinase
  • HY-162785

    CDK Infection
    XC219 (compound 43) is a cyclin-dependent kinase CDK) inhibitor, that covalently binds to CDK active site Lys. XC219 can be used in antifungal research .
    XC219
  • HY-160941

    CDK Cancer
    CDK2-IN-29 (Compound 13q) is an inhibitor for cyclin-dependent kinase (CDK), with IC50 of 96 nM and 360 nM, for CDK 2 and CDK 4, respectively .
    CDK2-IN-29
  • HY-E70657

    CDK Neurological Disease Cancer
    CDK10/CycQ Recombinant Human Active Protein Kinase is a cyclin-dependent kinase, which is important for neural development and can act as a tumour suppressor .
    CDK10/CycQ Recombinant Human Active Protein Kinase
  • HY-108348

    CDK Neurological Disease
    BML-259 is a potent cyclin-dependent kinase 5 (Cdk5) inhibitor, with IC50s of 64 and 98 nM for Cdk5 and Cdk2, respectively .
    BML-259
  • HY-E70674

    CDK Cancer
    CDK2 is a cyclin-dependent kinase involved in the control of the cell cycle. CDK2/CycO Recombinant Human Active Protein Kinase is an ortholog of CDK2 .
    CDK2/CycO Recombinant Human Active Protein Kinase
  • HY-E70672

    CDK Cancer
    CDK2 is a cyclin-dependent kinase involved in the control of the cell cycle. CDK2/CycE1 Recombinant Human Active Protein Kinase is an ortholog of CDK2 .
    CDK2/CycE1 Recombinant Human Active Protein Kinase
  • HY-124321

    CDK Cancer
    Metralindole hydrochloride is an inhibitor of human cyclin-dependent kinase CDK2 and human protein kinase CK2 holoenzyme. Metralindole hydrochloride shows good potential as a non-small cell lung cancer inhibitor .
    Metralindole hydrochloride
  • HY-E70673

    CDK Cancer
    CDK2 is a cyclin-dependent kinase involved in the control of the cell cycle. CDK2/CycE2 Recombinant Human Active Protein Kinase is an ortholog of CDK2 .
    CDK2/CycE2 Recombinant Human Active Protein Kinase
  • HY-E70671

    CDK Cancer
    CDK2 is a cyclin-dependent kinase involved in the control of the cell cycle. CDK2/CycD1 Recombinant Human Active Protein Kinase is an ortholog of CDK2 .
    CDK2/CycD1 Recombinant Human Active Protein Kinase
  • HY-124321A

    CDK Cancer
    Metralindole is an inhibitor of human cyclin-dependent kinase CDK2 and human protein kinase CK2 holoenzyme. Metralindole shows good potential as a non-small cell lung cancer inhibitor .
    Metralindole
  • HY-E70669

    CDK Cancer
    CDK2 is a cyclin-dependent kinase involved in the control of the cell cycle. CDK2/CycA1 Recombinant Human Active Protein Kinase is an ortholog of CDK2 .
    CDK2/CycA1 Recombinant Human Active Protein Kinase
  • HY-E70670

    CDK Cancer
    CDK2 is a cyclin-dependent kinase involved in the control of the cell cycle. CDK2/CycA2 Recombinant Human Active Protein Kinase is an ortholog of CDK2 .
    CDK2/CycA2 Recombinant Human Active Protein Kinase
  • HY-123369

    CDK Apoptosis Cancer
    BMI-1026 is a cyclin-dependent kinase 1 (Cdk1) inhibitor with IC50 of 2.3 nM. BMI-1026 induces apoptosis by arresting the G2-M phase .
    BMI-1026
  • HY-E70658

    CDK Cancer
    CDK12 R722C/CycK Recombinant Human Active Protein Kinase is a cyclin-dependent kinase and regulates the expression of genes involved in DNA repair and is required for the maintenance of genomic stability .
    CDK12 R722C/CycK Recombinant Human Active Protein Kinase
  • HY-118902

    CDK Others
    Aloisine B (compound 9) is a cyclin-dependent kinase (CDK) inhibitor. Aloisine B inhibits cell proliferation by arresting cells in both G1 and G2 via competing with ATP-binding pocket .
    Aloisine B
  • HY-141687

    CDK Apoptosis Cancer
    NSC 107512 is a potent inhibitor of cyclin-dependent kinase 9 (CDK9). NSC 107512 is a class of sangivamycin-like molecules (SLM). NSC 107512 inhibits growth and induces apoptosis of multiple myeloma tumors .
    NSC 107512
  • HY-E70656

    CDK Cancer
    CDK1 is a cyclin-dependent kinase that functions as a serine/threonine protein kinase, and is a key player in cell cycle regulation. CDK1/CycO Recombinant Human Active Protein Kinase is an ortholog of CDK1 .
    CDK1/CycO Recombinant Human Active Protein Kinase
  • HY-151371

    CDK Cancer
    CDK8-IN-10 (compound 2) is a potent, selective cyclin-dependent kinase (CDK8) inhibitor with an IC50 value of 8.25 nM. CDK8-IN-10 can be used for research of cancer .
    CDK8-IN-10
  • HY-19718

    TOPK CDK Apoptosis Cancer
    OTS964 is an orally active, high affinity and selective TOPK inhibitor with an IC50 of 28 nM . OTS964 is also a potent inhibitor of the cyclin-dependent kinase CDK11, which binds to CDK11B with a Kd of 40 nM .
    OTS964
  • HY-169344

    CDK Cancer
    CDK7-IN-31 (compound 13) is a potent and orally active cyclin-dependent kinase 7 (CDK7) inhibitor with a Kd value of 0.18 nM. CDK7-IN-31 shows anticancer activity .
    CDK7-IN-31
  • HY-112358

    CDK Neurological Disease Cancer
    GW8510 is a potent cyclin-dependent kinase-2 (CDK2) inhibitor. GW8510 is also a ribonucleotide reductase M2 (RRM2) inhibitor. GW8510 exhibits neuroprotective and anticancer activities .
    GW8510
  • HY-E70655

    CDK Cancer
    CDK1 is a cyclin-dependent kinase that functions as a serine/threonine protein kinase, and is a key player in cell cycle regulation. CDK1/CycE2 Recombinant Human Active Protein Kinase is an ortholog of CDK1 .
    CDK1/CycE2 Recombinant Human Active Protein Kinase
  • HY-162683

    CDK Neurological Disease Cancer
    (S)-PHA533533 is a cyclin-dependent kinase 2 (CDK2) inhibitor. (S)-PHA533533 shows anti-tumor activity and can induce widespread neuronal UBE3A expression in angelman syndrome model mice .
    (S)-PHA533533
  • HY-101257A

    CDK Cancer
    CDK7-IN-1, an analog of YKL-5-124, is a cyclin-dependent kinase 7 (cdk7) inhibitor, with an IC50 of less than 100 nM, extracted from patent WO 2016105528 A2, Compound 215 .
    CDK7-IN-1
  • HY-E70652

    CDK Cancer
    CDK1 is a cyclin-dependent kinase that functions as a serine/threonine protein kinase, and is a key player in cell cycle regulation. CDK4/CycD2 Recombinant Human Active Protein Kinase is an ortholog of CDK1 .
    CDK1/CycA2 Recombinant Human Active Protein Kinase
  • HY-E70651

    CDK Cancer
    CDK1 is a cyclin-dependent kinase that functions as a serine/threonine protein kinase, and is a key player in cell cycle regulation. CDK1/CycA1 Recombinant Human Active Protein Kinase is an ortholog of CDK1 .
    CDK1/CycA1 Recombinant Human Active Protein Kinase
  • HY-E70654

    CDK Cancer
    CDK1 is a cyclin-dependent kinase that functions as a serine/threonine protein kinase, and is a key player in cell cycle regulation. CDK1/CycA1 Recombinant Human Active Protein Kinase is an ortholog of CDK1 .
    CDK1/CycE1 Recombinant Human Active Protein Kinase
  • HY-137432A
    Avotaciclib trihydrochloride
    2 Publications Verification

    BEY1107 trihydrochloride

    CDK Apoptosis Cancer
    Avotaciclib (BEY1107) trihydrochloride is an orally active cyclin-dependent kinase 1 (CDK1) inhibitor. Avotaciclib trihydrochloride can inhibit the proliferation and induce apoptosis of tumor cells. Avotaciclib trihydrochloride can be used in the research of cancer such as pancreatic cancer and lung cancer .
    Avotaciclib trihydrochloride
  • HY-137432B
    Avotaciclib hydrochloride
    2 Publications Verification

    BEY1107 hydrochloride

    CDK Apoptosis Cancer
    Avotaciclib (BEY1107) hydrochloride is an orally active cyclin-dependent kinase 1 (CDK1) inhibitor. Avotaciclib hydrochloride can inhibit the proliferation and induce apoptosis of tumor cells. Avotaciclib hydrochloride can be used in the research of cancer such as pancreatic cancer and lung cancer .
    Avotaciclib hydrochloride
  • HY-137432
    Avotaciclib
    2 Publications Verification

    BEY1107

    CDK Apoptosis Cancer
    Avotaciclib (BEY1107) is an orally active cyclin-dependent kinase 1 (CDK1) inhibitor. Avotaciclib can inhibit the proliferation and induce apoptosis of tumor cells. Avotaciclib can be used in the research of cancer such as pancreatic cancer and lung cancer .
    Avotaciclib
  • HY-147409

    CDK Cancer
    Ulecaciclib is an orally activitive inhibitor of cyclin-dependent kinase (CDK), with Ki values of 0.62 μM (CDK2/Cyclin A), 0.2 nM (CDK4/Cyclin D1), 3 nM (CDK6/Cyclin D3), and 0.63 μM (CDK7/Cyclin H), respectively. Ulecaciclib can cross blood brain barrier and has good pharmacokinetic characteristics .
    Ulecaciclib
  • HY-162416

    CDK Cancer
    CDK7-IN-27 (Compound 37) is a selective inhibitor for cyclin-dependent kinase 7 (CDK7), with Ki of 3 nM. CDK7-IN-27 arrests the cell cycle at G0/G1 phase .
    CDK7-IN-27
  • HY-114177
    Ebvaciclib
    3 Publications Verification

    PF-06873600

    CDK Cancer
    PF-06873600 is a selective and orally bioavailable inhibitor of cyclin-dependent kinase (CDK), with Ki values of 0.09 nM, 0.13 nM and 0.16 nM for CDK2, CDK4 and CDK6, respectively. PF-06873600 has potential antineoplastic activity .
    Ebvaciclib
  • HY-137432D

    BEY1107 sulfate

    CDK Apoptosis Cancer
    Avotaciclib (BEY1107) sulfate is an orally active cyclin-dependent kinase 1 (CDK1) inhibitor. Avotaciclib sulfate can inhibit the proliferation and induce apoptosis of tumor cells. Avotaciclib sulfate can be used in the research of cancer such as pancreatic cancer and lung cancer .
    Avotaciclib sulfate
  • HY-E70659

    CDK Cancer
    CDK12/CycK Recombinant Human Active Protein Kinase is a cyclin-dependent kinase that phosphorylates the C-terminal domain (CTD) of RNA polymerase II (Pol II), thereby regulating different phases of the transcription cycle from transcription initiation to elongation and termination .
    CDK12/CycK Recombinant Human Active Protein Kinase
  • HY-171787

    CDK Cancer
    PPA-037 is an orally active, highly potent and selective inhibitor of cyclin-dependent kinase 12 (CDK12). PPA-037 induces the degradation of cyclin K (Cyclin K), enhancing antiproliferative effects on tumor cells. PPA-037 is promising for research of cancers .
    PPA-037

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: